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 Activation of ionotropic glutamate (Glu) receptors, such as N-methyl-D-aspartate 
receptors, is shown to modulate the gene transcription mediated by the transcription factor 
activator protein-1 (AP1) composed of Fos and Jun family proteins in the brain, while little 
attention has been paid to the modulation of AP1 expression by metabotropic Glu receptors 
(mGluRs). In cultured rat cortical neurons, where constitutive expression was seen with all 
group I, II and III mGluR subtypes, a significant and selective increase was seen in the DNA 
binding activity of AP1 120 min after the brief exposure to the group II mGluR agonist 
(2S,2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine (DCG-IV) for 5 min. In cultured rat 
cortical astrocytes, by contrast, a significant increase was induced by a group I mGluR agonist, 
but not by either a group II or III mGluR agonist. The increase by DCG-IV was significantly 
prevented by a group II mGluR antagonist as well as by either an intracellular Ca2+ chelator or 
a voltage-sensitive Ca2+ channel blocker, but not by an intracellular Ca2+ store inhibitor. 
Moreover, DCG-IV significantly prevented the increase of cAMP formation by forskolin in 
cultured neurons. Western blot analysis revealed differential expression profiles of Fos family 
members in neurons briefly exposed to DCG-IV and NMDA. Prior or simultaneous exposure 
to DCG-IV led to significant protection against neuronal cell death by NMDA. These results 
suggest that activation of the group II mGluR subtype would modulate the gene expression 





 Glutamate (Glu) receptors are categorized into the two major subclasses, ionotropic 
(iGluR) and metabotropic (mGluR) receptors, on the basis of intracellular signal transduction 
systems as well as nucleotide sequence homology. The mGluRs are a family of type III 
G-protein-coupled receptors activated by the excitatory amino acid neurotransmitter Glu, and 
classified into three major subtypes (group I, mGluR1 and 5 isoforms; group II, mGluR2 and 
3 isoforms; group III, mGluR4, 6, 7 and 8 isoforms) based on sequence homology, signal 
transduction pathway and pharmacology (Conn and Pin, 1997; Schoepp et al., 1999; Zhai et 
al., 2003). The group I mGluR subtype is coupled to stimulatory Gq proteins to activate 
phospholipase C, which catalyzes the production of diacylglycerol and inositol 
(1,4,5)-trisphosphate (IP3) for subsequent activation of protein kinase C and release of Ca2+ 
from intracellular stores, respectively. Both group II and III mGluR subtypes are coupled to 
the inhibitory Gi/o protein to negatively regulate the activity of adenylyl cyclase, which 
decreases intracellular concentrations of cAMP (Cartmell and Schoepp, 2000; Schoepp, 2001; 
Moldrich et al., 2003; Kenny and Markou, 2004).  
 These mGluR subtypes show an enormous diversity of effects on neurons and glia 
(Winder and Conn, 1996; Conn and Pin, 1997; Anwyl, 1999; Cartmell and Schoepp, 2000; 
Schoepp, 2001). Immunocytochemical studies reveal that the neuronal location varies in 
relation to the density of synaptic clefts with mGluR subtypes in the brain (Shigemoto and 
Mizuno, 2000; Moldrich et al., 2003). Group I mGluR isoforms are predominantly found at 
the postsynaptic location adjacent to the margins in the synaptic cleft, for example, while 
mGluR5, but not mGluR1, isoform is found in glia. The mGluR1α isoform is particularly 
localized to GABAergic interneurons in hippocampus and cerebellum (Shigemoto et al., 
1997), whereas mGluR5 isoform is highly expressed in the limbic cortex and basal ganglia. 
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The group II mGluR subtype predominates in presynaptic locations, with strong evidence for 
the location of mGluR2 isoform on presynaptic axons in cerebellum, neocortex and thalamus. 
While mGluR3 isoform shares a similar distribution pattern with mGluR2 isoform throughout 
the brain, this mGluR3 isoform is also expressed in glia (Tamaru et al., 2001). Although the 
group III mGluR subtype is basically presynaptic with the localization of mGluR4, mGluR7 
and mGluR8 isoform mRNA to the basal ganglia motor loop (Messenger et al., 2002), 
however, mGluR6 isoform expression appears to be largely restricted to retinal neurons 
(Moldrich et al., 2003).  
 The transcription factor activator protein-1 (AP1) is a homo- or hetero-dimer 
between Jun and Fos family members with affinity for the core nucleotide sequence 
TGACTCA at the upstream or downstream of inducible target genes (Curran and Franza, 
1988). Increased AP1 DNA binding would lead to long-lasting and sometimes permanent 
alterations of a variety of neuronal activities, such as neuronal plasticity and delayed neuronal 
death, following transient activation of iGluRs located at membranes in the brain. In fact, 
several independent lines of evidence indicate that activation of N-methyl-D-aspartate 
(NMDA) and kainate subtypes of iGluRs leads to a marked increase in the DNA binding 
activity of AP1 through up-regulation of particular Jun and Fos family member proteins in the 
brain in vivo and in vitro. However, relatively little attention has been paid to the modulation 
of expression of AP1 complex in response to activation of mGluR subtypes in the brain to 
date.  
 In this article, therefore, we have evaluated AP1 DNA binding following the 
activation of different mGluR subtypes to investigate the possible participation of gene 
transcription by the AP1 complex in mechanisms underlying the signal input mediated by 
mGluR subtypes across plasma membranes in primary cultured rat cortical neurons. 
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 Rabbit polyclonal antibodies against c-Fos, FosB, Fra-2, c-Jun, JunB and JunD 
proteins were all provided by Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). An 
anti-rabbit IgG antibody conjugated with peroxidase, ECLTM detection reagents, a QuickPrep 
Micro mRNA Purification Kit and a cAMP enzyme immunoassay system were supplied by 
Amersham Biosciences (Piscataway, NJ, USA). Versene, Dulbecco’s Modified Eagle 
Medium (DMEM) and DMEM: Nutrient Mixture F-12 (DMEM/F-12) 1:1 Mixture were 
purchased from GIBCO BRL (Gaithersburg, MD, USA). Fetal calf serum (FCS) was obtained 
from JRH Biosciences, Inc. (Lenexa, KS, USA). [α-32P]deoxy-ATP (111 MBq/mmol) was 
provided by PerkinElmer Life Sciences (Waltham, MA, USA). rTaq DNA Polymelase was 
supplied by TAKARA BIO, Inc. (Otsu, Japan). 
(RS)-1-Amino-5-phosphonpindan-1-carboxylic acid (APICA), 
(2S,2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine (DCG-IV), 3,5-dihydroxyphenylglycine 
(DHPG), L-2-amino-4-phosphonobutyrate (L-AP4) and NMDA were purchased from Tocris 
Cookson (Bristol, UK). Other chemicals used were all of the highest purity commercially 
available. 
 
2.2. Preparation of neuronal cultures 
 
 This study was carried out in compliance with the Guideline for Animal 
Experimentation at Kanazawa University with an effort to minimize the number of animals 
used and their suffering. Primary neuronal cultures were prepared from cerebral neocortex of 
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18-day-old embryonic rats as originally described by di Porzio et al. (1980) with several 
modifications (Nakamichi et al., 2002a, 2002b). In brief, cerebral neocortex was dissected 
from embryonic Wistar rats and incubated with Versene at room temperature for 12 min. 
Cells were then mechanically dissociated with a fire-narrowed Pasteur pipette in the culture 
medium, and plated at a density of 2.5×105 cells/cm2 on a 6-well or 24-well dish (NUNC, 
Roskilde, Denmark) after counting cell numbers with a Trypan Blue exclusion test. Prior to 
use, dishes were sequentially coated with 75 µg/ml poly-L-lysine. The culture medium 
contained basal DMEM/F-12 with supplementation by 10% FCS, 33 mM glucose, 2 mM 
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 5 mM HEPES and 0.11% sodium 
bicarbonate. Cells were treated with 10 µM cytosine arabinoside for 24 h during 2 to 3 days in 
vitro (DIV). Cultures were kept in serum free medium, basal DMEM with supplementation by 
25.5 mM glucose, 0.5 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.11% 
sodium bicarbonate, 50 µg/ml transferrin, 500 ng/ml insulin, 1 pM β-estradiol, 3 nM 
triiodothyronine, 20 nM progesterone, 8 ng/ml sodium seleniate and 100 µM putrescine after 
3 DIV. The culture medium was replaced with freshly prepared culture medium of the same 
composition every 3 days. Cultures were always maintained at 37°C in a 5% CO2/95% 
air-humidified incubator. Cortical neurons cultured for 14 DIV were usually used in this study 
unless otherwise indicated. 
 
2.3. Preparation of astrocyte cultures 
 
 Astrocytes were prepared as described previously (Murakami et al., 2003). In brief, 
brain cortices from 20-day-old embryos of Wistar rats were cleared of meninges, cut into 
about 1-mm3 blocks, and treated with 0.25% trypsin in Ca2+, Mg2+-free phosphate-buffered 
saline (PBS) containing 5.5 mM glucose for 20 min at 37°C with gentle shaking. An equal 
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volume of horse serum supplemented with 0.1 mg/ml of DNase I was added to the medium to 
inactivate trypsin. Then, tissues were centrifuged at 1,500×g for 5 min. The tissue sediments 
were triturated through a Pasteur pipette with DMEM containing 10% FCS, 100 mg/l 
streptomycin, and 5×104 unit/l penicillin. After filtration of cell suspensions through a 
lens-cleaning paper (Fuji Photo, Tokyo, Japan), cells were plated on 
polyethyleneimine-coated 100 mm-diameter plastic dishes (NUNC, Roskilde, Denmark) at a 
density of 0.8-1.3×105 cells/cm2. Cultures were maintained in a humidified atmosphere of 5% 
CO2 and 95% air at 37°C with changing medium every 3 days. After one week, astrocytes 
were replated to remove neurons. On days 12 to 14, they were again replated onto a 6-well 
dish using an ordinary trypsin-treatment technique at a density of 0.8-1.3×105 cells/cm2 and 
cultured for additional one week. 
 
2.4. Reverse transcription polymerase chain reaction (RT-PCR) 
 
 We used a QuickPrep Micro mRNA Purification Kit (Amersham Biosciences; 
Piscataway, NJ, USA) to extract mRNA from rat whole brain, cultured cortical neurons and 
astrocytes, and mRNA was then subjected to the synthesis of cDNA. The individual cDNA 
species were amplified in a reaction mixture containing a cDNA aliquot, PCR buffer, dNTPs, 
the relevant sense and antisense primers (mGluR1 subunit: 
5’-CCAGTGATGTTCTCCATACC-3’ and 5’-CACTCTGGGTAGACTTGAGTG-3’; 
mGluR2 subunit: 5’-TTTAGGTCAGAAGCCAGAGT-3’ and 
5’-CAGTAACCATCCTCTCTATCC-3’; mGluR3 subunit: 
5’-TATTCTCAGTCCTCTGCAAG-3’ and 5’-TTGTAGCACATCACTACATACC-3’; 
mGluR4 subunit: 5’-TCATTTTCTCTTCTGTTCCC-3’ and 
5’-GACATGCTACACATCAGAGAC-3’; mGluR5 subunit: 
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5’-CCCCAAACTCTCCAGTCT-3’ and 5’-ATTTTTCACCTCGGGTTC-3’; mGluR6 
subunit: 5’-CAAGTAGCAAGGTTGAGTGT-3’ and 5’-GGTTGTAGTGTTGGATCAAG-3’; 
mGluR7 subunit: 5’-GAACTCTGTGAAAATGTAGACC-3’ and 
5’-TTAGGGAGTCCAGAATTACAG-3’; mGluR8 subunit: 
5’-CGAGGGTTATAACTACCAGGT-3’ and 5’-TAGGTGCTGTGACAGATTTCT-3’) and 
rTaq DNA Polymerase. Reactions were initiated by incubating at 95°C for 5 min and PCR 
(denaturation at 95°C for 1 min, annealing at 50°C for 1 min and extension at 75°C for 2 min, 
respectively) was performed for a suitable number of cycles with a final extension at 75°C for 
10 min. The PCR products were determined on 2% agarose gel electrophoresis and visualized 
by ethidium bromide. 
 
2.5. Preparation of nuclear extracts 
 
 Nuclear fractions were prepared according to the method of Schreiber et al. (1989), 
with minor modifications (Yoneda and Ogita, 1994; Hirai et al., 2002). Cortical neurons were 
exposed to one of mGluR agonists for 5 min, followed by washing and subsequent further 
incubation for 120 min. Cells were harvested with a rubber policeman and homogenized in 
500 µl of 10 mM HEPES-NaOH buffer (pH 7.9) containing 10 mM KCl, 1 mM EDTA, 1 mM 
EGTA, 5 mM dithiothreitol (DTT), 10 mM NaF, 10 mM sodium β-glycerophosphate (NaGP) 
and 1 µg/ml of following protease inhibitors; (p-amidinophenyl)methanesulfonyl fluoride, 
benzamidine, leupeptin and antipain. Following the addition of 10% Nonidet P-40 to make a 
final concentration of 0.6%, homogenates were centrifuged at 20,000×g for 5 min. Pellets 
were suspended in 20 µl of 50 mM Tris-HCl buffer (pH 7.5) containing 400 mM KCl, 1 mM 
EDTA, 1 mM EGTA, 5 mM DTT, 10% (v/v) glycerol, 10 mM NaF, 10 mM NaGP and the 
aforementioned protease inhibitors, followed by the centrifugation at 20,000×g for 5 min. 
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Supernatants thus obtained were stored at -80°C as nuclear extracts until use. Protein 
concentration was determined by Bio-Rad Protein assay kit (Bio-Rad; Hercules, CA, USA) 
and adjusted at 3 µg in 8 µl of incubation buffer. 
 
2.6. Preparation of probe 
 
 The probe for determination of AP1 binding was double stranded oligonucleotides 
with 22 mer (5’-CTAGTGATGAGTCAGCCGGATC-3’/ 
3’-GATCACTACTCAGTCGGCCTAG-5’) that was radiolabeled with [α-32P]deoxy-ATP 
using Klenow fragment of DNA polymerase I in 10 mM Tris–HCl buffer (pH 7.4) containing 
50 mM NaCl, 10 mM MgCl2, 1 mM DTT and 50 µM deoxy-GTP, deoxy-CTP and 
deoxy-TTP at 25°C for 30 min, followed by the purification with gel filtration 
chromatography on a Nick column (Ogita and Yoneda, 1994). The term “AP1 DNA binding” 
was used to refer to binding of a radiolabeled probe for AP1 complex throughout the paper. 
 
2.7. Gel retardation electrophoresis 
 
 An aliquot of nuclear extracts (3 µg protein in 8 µl) was mixed with 10 µl of 0.1 
mg/ml poly(dI-dC), 50 mM Tris–HCl buffer (pH 7.5), 20 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA, 5 mM DTT, 10% glycerol and 1 µg/ml protease inhibitors, followed by the incubation 
with 2 µl of 20 fmol of radiolabeled probe (0.5-5.0 × 106 cpm/pmol) at 25°C for 30 min 
(Ogita and Yoneda, 1994). Bound and free probes were separated by electrophoresis on a 6% 
polyacrylamide gel in 50 mM Tris-HCl (pH 8.5), 0.38 M glycine and 2 mM EDTA at a 
constant voltage of 11 V/cm for 1.5 h in an ice bath. Gels were fixed, dried and exposed to an 
X-ray film for autoradiography. Gels were always exposed to X-ray films for different periods 
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to obtain autoradiograms adequate for quantitative densitometric analysis. 
 
2.8. Quantification of cAMP 
 
Cortical neurons cultured for 14 DIV were washed twice with PBS and incubated in 
PBS containing 1 mM 3-isobutyl-1-methylxanthine (IBMX), an inhibitor of 
phosphodiesterase, for 20 min at 37°C under 5% CO2, followed by the addition of 10 µM 
forskolin in either the presence or absence of DCG-IV at 100 µM in PBS containing 1 mM 
IBMX for 5 min at 37°C under 5% CO2, as described previously (Fujimori et al., 2002). After 
the stimulation, cells were sonicated in lysis buffer [0.25% solution of 
dodecyltrimethylammonium bromide in 0.05 M acetate buffer; 0.02% (w/v) bovine serum 
albumin; 0.01% (w/v) preservative]. Measurement of cAMP was conducted by enzyme 
immunoassay according to the manufacturer’s instructions. 
 
2.9. Western blotting 
 
 Cortical neurons were exposed to NMDA at 100 µM in the absence of Mg2+ ions or 
DCG-IV at 100 µM in the presence of Mg2+ ions for 5 min, followed by washing and 
subsequent further incubation for 120 min. Cells harvested with a rubber policeman were 
homogenized in 20 mM Tris-HCl buffer (pH 7.5) containing 1 mM EDTA, 1 mM EGTA, 10 
mM NaF, 10 mM NaGP, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate and 1 
µg/ml of various protease inhibitors [(p-amidinophenyl)methanesulfonyl fluoride, leupeptin, 
antipain and benzamidine], followed by the addition of 10 mM Tris-HCl buffer (pH 6.8) 
containing 10% glycerol, 2% sodium dodecylsulfate (SDS), 0.01% bromophenol blue and 5% 
2-mercaptoethanol (SDS sample buffer) at a volume ratio of 4:1 and subsequent boiling at 
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100°C for 10 min (Manabe et al., 2001). Each aliquot of 20 µg proteins was loaded on a 7.5% 
polyacrylamide gel for the electrophoresis at a constant current of 15 mA/plate for 2 h at room 
temperature and subsequent blotting to a polyvinylidene fluoride membrane previously 
treated with 100% methanol. After blocking by 5% skimmed milk dissolved in 20 mM 
Tris-HCl buffer (pH 7.5) containing 137 mM NaCl and 0.05% Tween 20, the membrane was 
reacted with an antibody against c-Fos, FosB, Fra-2, c-Jun, JunB or JunD, adequately diluted 
with the buffer containing 1% skim milk, followed by the reaction with an anti-rabbit IgG 
antibody conjugated with peroxidase. Proteins reactive with those antibodies were detected 
with the aid of ECLTM detection reagents through exposure to X-ray films. 
 
2.10. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay 
 
 Cellular viability was assessed by the MTT reduction assay for the mitochondrial 
activity as described previously (Nakamichi et al., 2005). Cultured cells were washed once 
with PBS and incubated with 0.5 mg/ml MTT in PBS for 1 h at 37°C, followed by the 
addition of 0.04 M HCl in isopropyl alcohol to the well and subsequent shaking of the 
mixture for 10 min to dissolve the formazan. The dissolved suspension was subjected to an 
enzyme-linked immunosorbent assay reader and the absorbance at a wavelength of 550 nm 
was measured. 
 
2.11. Drug treatments 
 
 Cultured cells were washed twice with HEPES-Krebs Ringer buffer (HKR; 130 mM 
NaCl, 5.3 mM KCl, 0.8 mM MgSO4, 1.8 mM CaCl2, 1 mM NaH2PO4, 5.6 mM glucose, 50 
mM HEPES), followed by the prior incubation at 37°C for 15 min in HKR under the 
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humidified atmosphere of 5% CO2. For NMDA treatment, MgSO4 was omitted from HKR 
during the incubation. A test drug was then added into the incubation medium for the brief 
exposure for 5 min, followed by the rapid washing of cells with ice-cold Ca2+, Mg2+-free PBS 
and subsequent placement of culture plates on ice. The cell monolayer was rapidly scraped in 
ice-cold extract or lysis buffer. Drugs were freshly made on the day of the experiment. All 
mGluR agonists were used at 100 µM unless otherwise indicated, for DCG-IV was most 
efficient at 100 µM in increasing AP1 DNA binding as shown below.  
 
2.12. Data analysis 
 
 Densitometric data were subjected to calculation of the area under the curve using 
Scion Image β 4.02 software (Scion Co., Frederick, MD, USA). For samples on the same gel, 
the area was directly used as a densitometric unit for quantitative analysis. Results are all 
expressed as the mean ± S.E. and the statistical significance was determined by the one-way 




3.1. Changes in AP1 DNA binding by mGluR agonists 
 
 In order to examine the expression of mRNA for mGluR isoforms during in vitro 
maturation, RT-PCR analysis was done using primers specific for each mGluR isoform in rat 
cortical neurons cultured for 3 to 14 DIV. As shown in Fig. 1A, constitutive mRNA 
expression was seen for all mGluR isoforms in neurons cultured for 3 to 14 DIV. Cortical 
neurons cultured for 14 DIV were then exposed to one of the mGluR agonists at 100 µM for 5 
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min, followed by the further incubation for an additional 120 min and subsequent cell harvest 
for the preparation of nuclear extracts to measure AP1 DNA binding on gel retardation 
electrophoresis. Of agonists tested, the group II mGluR agonist DCG-IV, but neither the 
group I mGluR agonist DHPG nor the group III mGluR agonist L-AP4, significantly 
increased AP1 DNA binding in cultured neurons (Fig. 1B). In cultured rat cortical astrocytes, 
by contrast, mRNA expression was only seen with mGluR5, mGluR3 and mGluR6 isoforms, 
but not with other mGluR isoforms (Fig. 2A). Of mGluR agonists tested, only DHPG was 
efficient in significantly increasing AP1 DNA binding with other mGluR agonists being 
ineffective in astrocytes (Fig. 2B). 
 
3.2. Activation of group II mGluR subtype in neurons 
 
 The brief exposure to DCG-IV significantly increased AP1 DNA binding in a 
concentration-dependent manner at a concentration range of 1 to 100 µM (Fig. 3A). This 
increase by DCG-IV was prevented to the control level by the prior addition of the group II 
antagonist APICA, while APICA alone did not markedly affect AP1 DNA binding (Fig. 3B). 
Quantitative analysis clearly revealed that DCG-IV significantly increased AP1 DNA binding 
in an APICA-sensitive manner (Fig. 3C). In cortical neurons cultured for 14 DIV, the cAMP 
level was 13.7±2.6 fmol/well when determined in the presence of the phosphodiesterase 
inhibitor IBMX alone. The addition of 10 µM forskolin drastically increased the endogenous 
level of cAMP to 1139.9±295.9 fmol/well, while the further addition of DCG-IV significantly 
inhibited the increase by forskolin at 100 µM (424.9±74.4 fmol/well) (Fig. 3D).  
 
3.3. AP1 complex 
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 In order to compare the constituent member proteins of the inducible AP1 complex, 
cortical neurons were exposed to 100 µM NMDA in the absence of Mg2+ ions or 100 µM 
DCG-IV in the presence of Mg2+ ions for 5 min, followed by the further incubation for an 
additional 120 min and subsequent cell harvest for the determination of AP1 component 
proteins on Western blot analysis. Both NMDA and DCG-IV drastically increased 
immunoreactivities to c-Fos protein, while expression of immunoreactive Fra-2 protein was 
significantly increased by NMDA but not by DCG-IV (Fig. 4A). Neither NMDA nor DCG-IV 
significantly affected expression of immunoreactive FosB protein. Both NMDA and DCG-IV 
significantly increased immunoreactivities to JunB protein, while neither DCG-IV nor 
NMDA significantly affected the expression of immunoreactive c-Jun and JunD (Fig. 4B). 
 
3.4. Possible involvement of intracellular calcium 
 
 Cortical neurons were exposed to different calcium blockers 10 min before the 
exposure to 100 µM DCG-IV for 5 min, followed by the further incubation for an additional 
120 min and subsequent cell harvest for the determination of AP1 DNA binding on gel 
retardation electrophoresis. Prior addition of either the intracellular Ca2+ chelator 
1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis acetoxymethyl ester 
(BAPTA-AM) (Fig. 5A) or the L-type voltage-sensitive Ca2+ channel blocker nifedipine (Fig. 
5C) significantly prevented the increase in AP1 DNA binding by DCG-IV at concentrations 
above 50 µM. However, the inhibitor of Ca2+ release across ryanodine-sensitive Ca2+ channel 
from intracellular stores dantrolene was ineffective in significantly inhibiting the increase by 
DCG-IV even at the highest concentration used (Fig. 5B). Either BAPTA-AM or nifedipine at 
100 µM was also effective in significantly decreasing AP1 DNA binding alone, with 
dantrolene alone being ineffective.  
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3.5. Protection against cell death by NMDA 
 
 In order to confirm the neuroprotective property of the group II mGluR subtype, 
cellular viability was determined in neurons exposed to 100 µM NMDA for 30 min in either 
the presence or absence of 100 µM DCG-IV, followed by the further incubation for an 
additional 24 h and subsequent determination of MTT reduction. In neurons exposed to 
NMDA alone in the presence of Mg2+, a slight and statistically insignificant decrease was 
seen in the MTT reduction activity (Fig. 6A). In the presence of Mg2+, however, a significant 
increase was induced in the MTT reduction activity by both prior and simultaneous exposures 
to DCG-IV, but not by the later exposure, compared to the activity in neurons exposed to 
NMDA alone. In cells exposed to NMDA alone in the absence of Mg2+, by contrast, a 
significant decrease was seen in the MTT reducing activity, which was significantly 
prevented by prior and simultaneous, but not later, exposure to DCG-IV (Fig. 6B). Exposure 




 The essential importance of the present findings is that activation of the group II 
mGluR subtype led to a significant increase in AP1 DNA binding through expression of 
particular Fos and Jun family member proteins in association with increased intracellular free 
Ca2+ levels in cultured rat neocortical neurons. The data from pharmacological evaluation 
give support for the possible involvement of voltage-sensitive Ca2+ channels, rather than 
intracellular Ca2+ stores, in mechanisms underlying the increase of AP1 DNA binding after 
activation of the group II mGluR subtype. However, Western blot analysis suggests that the 
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group II mGluR subtype would increase AP1 DNA binding through a mechanism different 
from that by NMDA receptor channels highly permeable to this divalent cation. There is 
accumulating evidence for the correlation between activation of the group I mGluR subtype 
and expression of the AP1 complex. Activation of the group I mGluR subtype could affect 
Ca2+ homeostasis at multiple levels with expression of both c-fos mRNA and c-Fos protein in 
striatal neurons (Mao and Wang, 2003), for example, while pretreatment with a group I 
mGluR subtype antagonist completely blocks morphine-induced c-Fos protein expression in 
the caudate-putamen (Garcia et al., 2003). Selective activation of the mGluR5 isoform 
induces a rapid and transient phosphorylation of c-Jun N-terminal kinase, followed by the 
induction of c-Jun protein and subsequent increase in AP1 expression in cultured neurons 
(Yang et al., 2006). 1S,3R-1-Amino-cyclopentane-1,3-dicarboxylate, a non-selective agonist 
for mGluRs, induces a rapid and transient expression of c-fos, fosB and junB mRNA, with 
increasing AP1 DNA binding in primary astroglial cultures (Condorelli et al., 1993). 
Therefore, it is highly conceivable that activation of the group I mGluR subtype would lead to 
upregulation of the AP1 complex composed of both Fos and Jun family member proteins 
through a mechanism related to an increased free Ca2+ level mediated by the promoted release 
from intracellular stores after the activation of this subtype. Since supershift analysis is often 
insufficient for the clear demonstration of the differential induction profiles, Western blot 
analysis was employed for the direct demonstration of differential expression profiles of Fos 
and Jun family member proteins in response to the activation of group II mGluR and NMDA 
receptor subtypes in the present study.  
 In addition to the aforementioned group I mGluR subtype linked to the formation of 
IP3 responsible for the release of Ca2+ from intracellular stores, other mGluR subtypes are also 
shown to be involved in the expression of AP1 complex in the brain. Administration of a 
potent and selective agonist for the group II mGluR subtype decreases stress-induced 
 18
increases in c-Fos protein expression in the CA3 subfield of the hippocampus, but 
significantly increases c-Fos protein expression in several other stress-sensitive brain regions 
(Linden et al., 2004). Systemic administration of an mGluR8 isoform agonist significantly 
increases c-Fos protein in stress-related brain regions in wild-type mice, but not in 
mGluR8-null mice (Linden et al., 2003). To our knowledge, this is the first direct 
demonstration of upregulation of the AP1 complex consisting of c-Fos and JunB proteins 
through a mechanism relevant to increased intracellular free Ca2+ levels after activation of the 
group II mGluR subtype negatively coupled to the formation of cAMP in cultured rat cortical 
neurons. From the data cited in the present study, the involvement of voltage-sensitive Ca2+ 
channels in the upregulation is highly conceivable. The exact mechanism as well as the 
functional significance of the transformation of cAMP signals mediated by the group II 
mGluR subtype into intracellular Ca2+ signals, however, remains to be elucidated in future 
studies. The presence of two different bands of mGluR3 mRNA in cultured astrocytes could 
be account for by taking into consideration the possible differential expression between 
neurons and astrocytes of alternative splicing variants of mGluR3 isoform (Sartorius et al., 
2006).  
 Several independent lines of evidence indicate the facilitation of Ca2+ influx across 
voltage-sensitive Ca2+ channels through the phosphorylation mediated by cAMP-dependent 
protein kinase (PKA). For instance, phosphorylation of the pore-forming subunit (=α1 
subunit) (Hell et al., 1993) is shown to induce enhancement of whole-cell Ca2+ currents 
carried by the L-type Ca2+ channels in different tissues (Gross et al., 1990; Trautwein and 
Hescheler, 1990; Hartzell et al., 1991). The present idea that activation of the group II mGluR 
subtype leads to the promotion of Ca2+ influx through voltage-sensitive Ca2+ channels toward 
subsequent induction of the AP1 complex in cultured neurons, by contrast, is not prevailing. 
The group II mGluR subtype has been indeed believed to decrease the phosphorylation 
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mediated by PKA through a decreased cAMP level after the negative regulation of adenylyl 
cyclase in an inhibitory Gi/o protein-dependent manner (Cartmell and Schoepp, 2000; Schoepp, 
2001; Moldrich et al., 2003; Kenny and Markou, 2004). The differential profile of AP1 
complex induction by group II and III mGluR subtypes in cultured neurons and astrocytes, 
therefore, argues in favor of an idea that the mechanism underlying the transformation of 
cAMP signals into Ca2+ signals in the cytoplasm could be different from cell to cell depending 
on prevailing conditions.  
 The reason why the decreased intracellular cAMP level is associated with an 
increased intracellular free Ca2+ level is not clarified so far. Although an unidentified protein 
could mediate the signal flow from cAMP to voltage-sensitive Ca2+ channels in cortical 
neurons, but not in astrocytes, in addition to PKA, the possibility that the decreased cAMP 
level is not relevant to the increased intracellular free Ca2+ level after activation of the group 
II mGluR subtype is not ruled out. However, it is unlikely that βγ subunits of the inhibitory 
Gi/o protein would be responsible for the increased intracellular free Ca2+ level after activation 
of the group II mGluR subtype in neurons. In case of GABAB receptors similarly linked to the 
inhibitory Gi/o protein, for example, an agonist could lead to the inhibition of voltage-sensitive 
Ca2+ channels and the activation of voltage-sensitive K+ channels through the βγ subunits, in 
addition to the inhibition of adenylyl cyclase by the α subunit, toward subsequent 
hyperpolarization in neurons (Bowery et al., 2002). Taken together, cAMP formation should 
be under the tonic stimulation by particular intracellular signals for an agonist of the group II 
mGluR subtype negatively linked to adenylyl cyclase to elicit pharmacological actions in any 
types of cells. An alternative possibility that the group II mGluR subtype might be linked to 
the inhibitory Gi/o protein toward subsequent activation of voltage-sensitive Ca2+ channels, 
nevertheless, is inconceivable.   
 It thus appears that activation of the group II mGluR subtype would induce the AP1 
 20
complex through a mechanism related to an increased intracellular free Ca2+ level after the 
promoted influx across the nifedipine-sensitive channels in cultured neurons. As neuronal cell 
death would undoubtedly involve mechanisms relevant to overshooting of intracellular free 
Ca2+ levels, elucidation of the protection mechanism could give us a new point of view 
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Fig. 1. Effects of mGluR agonists on AP1 DNA binding in cultured neurons. (A) Cortical 
neurons were cultured for 3 to 14 DIV, followed by extraction of mRNA for RT-PCR using 
primers specific for each mGluR isoform. PCR products were determined on 2% agarose gel 
electrophoresis and visualized by ethidium bromide. A representative observation is shown 
with similar results in 3 independent experiments. (B) Cortical neurons were cultured for 14 
DIV and exposed to the mGluR agonists DHPG (group I), DCG-IV (group II) and L-AP4 
(group III) at 100 µM for 5 min. After washing, neurons were further incubated for an 
additional 120 min and harvested for preparation of nuclear extracts to determine AP1 DNA 
binding on gel retardation electrophoresis. F(3,12) = 7.756, P<0.01. Values are the mean ± S.E. 
of percentages over the control value obtained in cells not exposed to any mGluR agonists in 
4 independent determinations. **P<0.01, significantly different from the control group. 
 
Fig. 2. Effects of mGluR agonists on AP1 DNA binding in cultured astrocytes. (A) Cortical 
astrocytes were subjected to extraction of mRNA for RT-PCR using primers specific for each 
mGluR isoform. PCR products were determined on 2% agarose gel electrophoresis and 
visualized by ethidium bromide. A representative observation is shown with similar results in 
3 independent experiments. (B) Cortical astrocytes were exposed to the mGluR agonists 
DHPG (group I), DCG-IV (group II) and L-AP4 (group III) at 100 µM for 5 min. After 
washing, cells were further incubated for 120 min and harvested for preparation of nuclear 
extracts to determine AP1 DNA binding on gel retardation electrophoresis. F(3,12) = 11.657, 
P<0.01. Values are the mean ± S.E. of percentages over the control value obtained in 
astrocytes not exposed to any mGluR agonists in 4 independent determinations. *P<0.05, 
significantly different from the control group.  
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Fig. 3. Activation of group II mGluR in cultured neurons. Cortical neurons were cultured for 
14 DIV, followed by exposure to DCG-IV at a concentration range of 1 to 200 µM for 5 min 
(A) or DCG-IV at 100 µM for 5 min in either the presence or absence of APICA at 100 µM 
(B, C). After washing, neurons were further incubated for an additional 120 min and 
harvested for preparation of nuclear extracts to determine AP1 DNA binding activity on gel 
retardation electrophoresis. Typical autoradiogram is shown in the panel (B), while 
quantitative dare are shown as the mean ± S.E. of percentages over the control value obtained 
in neurons not exposed to DCG-IV in 4 independent determinations in the panel (C). F(3,12) = 
6.971, P<0.01. *P<0.05, significantly different from each control values. #P<0.05, 
significantly different from the value obtained in neurons exposed to DCG-IV alone. (D) 
Cortical neurons cultured for 14 DIV were exposed to forskolin (FK) at 10 µM in either the 
presence or absence of DCG-IV at 100 µM for 5 min. Cells were washed, followed by cell 
harvest and subsequent measurement of cAMP concentrations. F(2,9) = 21.859, P<0.01. Values 
are the mean ± S.E. of percentages over the control value obtained in neurons not exposed to 
FK in 4 independent determinations. *P<0.05, significantly different from each control value. 
#P<0.05, significantly different from the value obtained in neurons exposed to FK alone.  
 
Fig. 4. Effects of DCG-IV and NMDA on expression of AP1 complex proteins. Cortical 
neurons cultured for 14 DIV were exposed to DCG-IV or NMDA at 100 µM for 5 min, 
followed by washing and subsequent culture for an additional 120 min toward SDS-PAGE for 
Western blotting using antibodies against (A) Fos family member proteins (c-Fos, FosB and 
Fra2) and (B) Jun family member proteins (c-Jun, JunB and JunD). F(2,9) = 19.577, P<0.01 for 
c-Fos; F(2,9) = 8.999, P<0.01 for Fra-2; F(2,9) = 42.553, P<0.01 for JunB. Values are the mean 
± S.E. of percentages over the control value obtained in neurons not exposed to a GluR 
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agonist in 4 independent determinations. *P<0.05, **P<0.01, significantly different from each 
control value. 
 
Fig. 5. Effects of calcium blockers on DCG-IV-induced increase in AP1 DNA binding. 
Cortical neurons cultured for 14 DIV were exposed to DCG-IV at 100 µM for 5 min in either 
the presence or absence of (A) BAPTA-AM, (B) dantrolene and (C) nifedipine at a 
concentration range of 10 to 100 µM. After washing, neurons were further incubated for an 
additional 120 min and harvested for preparation of nuclear extracts to determine AP1 DNA 
binding on gel retardation electrophoresis. F(5,18) = 9.381, P<0.01 for BAPTA-AM; F(5,24) = 
15.759, P<0.01 for dantrolene; F(5,18) = 3.459, P<0.05 for nifedipine. Values are the mean ± 
S.E. of percentages over the control value obtained in neurons not exposed to either DCG-IV 
or Ca2+ blocker in 4 or 5 independent determinations. *P<0.05, **P<0.01, significantly 
different from the control value. #P<0.05, ##P<0.01, significantly different from the value 
obtained in neurons exposed to DCG-IV alone. 
 
Fig. 6. Effects of DCG-IV on NMDA-induced cell death. Cortical neurons cultured for 14 
DIV were exposed to 100 µM NMDA for 30 min in either the (A) presence or (B) absence of 
Mg2+, followed by the further incubation for an additional 24 h and subsequent determination 
of cellular viability with MTT reduction assays. Neurons were also exposed to 100 µM 
DCG-IV 10 min before (pre), simultaneously (sim) or immediately (post) after the exposure 
to NMDA. F(5,18) = 4.489, P<0.01 for the presence of Mg2+; F(5,18) = 3.562, P<0.05 for the 
absence of Mg2+. Values are the mean ± S.E. of percentages over the control value obtained in 
neurons not exposed to either NMDA or DCG-IV in 4 independent determinations. **P<0.01, 
significantly different from each control value. #P<0.05, ##P<0.01, significantly different from 
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